ASCO Annual Meeting
ASCO Annual Meeting
Source/Disclosures
Source:

Keam B, et al. Abstract 6503. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.

Disclosures: Adenoid Cystic Carcinoma Research Foundation supported this study. Keam reports consultant/advisory roles with ABL Bio, AstraZeneca, Cellid, Genexin and MSD Oncology; and research funding from AstraZeneca, MSD Oncology and Ono Pharmaceutical. Please see the abstract for all other researchers’ relevant financial disclosures.
May 31, 2020
2 min read
Save

Axitinib prolongs PFS in metastatic adenoid cystic carcinoma

Source/Disclosures
Source:

Keam B, et al. Abstract 6503. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.

Disclosures: Adenoid Cystic Carcinoma Research Foundation supported this study. Keam reports consultant/advisory roles with ABL Bio, AstraZeneca, Cellid, Genexin and MSD Oncology; and research funding from AstraZeneca, MSD Oncology and Ono Pharmaceutical. Please see the abstract for all other researchers’ relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Axitinib significantly extended PFS among patients with recurred or metastatic adenoid cystic carcinoma, according to results of a randomized phase 2 study presented during the ASCO20 Virtual Scientific Program.

“Adenoid cystic carcinoma arises from the salivary gland with a broad spectrum of disease course that has a low response to cytotoxic chemotherapy and targeted agents,” Bhumsuk Keam, MD, PhD, medical oncologist at Seoul National University Hospital in Seoul, South Korea, said during a presentation. “The role of anti-angiogenic agents has been evaluated in single-arm phase 2 trials. However, the role of chemotherapy is still controversial, because of natural stable disease course without chemotherapy. Therefore, a randomized trial is absolutely needed.”

Keam and colleagues conducted the multicenter, prospective, open-label trial to evaluate the efficacy of axitinib, a small molecule tyrosine kinase inhibitor, compared with observation among 57 patients (median age, 56 years; range, 26-77; 53.3% women) with recurred or metastatic adenoid cystic carcinoma who progressed within 9 months. Three-quarters of patients had an ECOG performance status of 1.

Researchers randomly assigned patients 1:1 to 5 mg twice-daily axitinib (Inlyta, Pfizer) or observation, with permission for patients in the observation group to cross over to the treatment group if their disease progressed.

Researchers assessed treatment response every 8 weeks per RECIST version 1.1 and safety per NCI-Common Terminology Criteria for Adverse Events version 4.0.

Six-month PFS served as the primary endpoint. Secondary endpoints included objective response rate, OS, PFS, duration of response and adverse events.

Median follow-up was 25.4 months.

Results showed a 6-month PFS rate of 73.2% (95% CI, 54.8-88.1) with axitinib vs. 23.2% (95% CI, 9.3-41.1) with observation (HR = 0.19; 95% CI, 0.08-0.45).

Median PFS was 10.8 months with axitinib vs. 2.8 months with observation (HR = 0.25; 95% CI, 0.14-0.48). The ORR was 3.3% (95% CI, 0.1-17.2) with axitinib vs. 0% (95% CI, 0-12.8) with observation.

Disease control rates were 100% (95% CI, 88.4-100) in the axitinib group vs. 51.9% (95% CI, 32-71.3) in the observation group.

Among the 26 patients who crossed over from observation to the axitinib group, the ORR was 11.5%. Median OS was 27.2 months (95% CI, 20.2-32.8) in the observation group vs. not reached in the axitinib group (HR = 0.6; 95% CI, 0.26-1.38).

Common grade 1 to grade 2 adverse events in the axitinib group included oral mucositis and fatigue.

PAGE BREAK

Results of an analysis using pre-axitinib tissue samples of 28 patients showed common mutations, including ARID1B (28.6%), KDM6A and PARP4 (21.4%) and NOTCH1, MLL2, MLL3 and SFB1 (7.8%). Researchers noted that mutation burden or any specific mutation did not correlate with response or PFS.

“In this first-ever randomized trial in patients with recurred or metastatic adenoid cystic carcinoma, axitinib showed significantly increased 6-month PFS compared with observation and toxicity was overall well-tolerated,” Keam said. “Axitinib is a promising option to control adenoid cystic carcinoma disease progression and a randomized, prospective, phase 3 trial is warranted.” – by Jennifer Southall

Reference:

Keam B, et al. Abstract 6503. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.

Disclosures: Adenoid Cystic Carcinoma Research Foundation supported this study. Keam reports consultant/advisory roles with ABL Bio, AstraZeneca, Cellid, Genexin and MSD Oncology; and research funding from AstraZeneca, MSD Oncology and Ono Pharmaceutical. Please see the abstract for all other researchers’ relevant financial disclosures.